The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
Open accessAbstract
Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control. A small number of regulatory factors influence transcription elongation on a global scale. Prior research using small-molecule BET bromodomain inhibitors, such as JQ1, linked BRD4 to context-specific elongation at a limited number of genes associated with massive enhancer regions. Here, the mechanistic characterization of an optimized chemical degrader of BET bromodomain proteins, dBET6, led to the unexpected identification of BET proteins as master regulators of global transcription elongation. In contrast to the selective effect of bromodomain inhibition on transcription, BET degradation prompts a collapse of global elongation that phenocopies CDK9 inhibition. Notably, BRD4 loss does not directly affect CDK9 localization. These studies, performed in translational models of T cell leukemia, establish a mechanism-based rationale for the development of BET bromodomain degradation as cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“we focused on two BET Bromodomain targeting PROTACs: dBET6 (CRBN-based) and ARV-771 (VHL-based) that have matched cellular potency, including in the near-haploid human leukemia cell line KBM7 (Extended Data Fig. 1A)26,27.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [27]
In the citing paper
“These differences could be attributed to the distinct recruitment ligases used by MZ1 (VHL) or dBET6 (CRBN), as well as the established differences in selectivity for the BBDs, where MZ1 preferentially degrades BRD4 (17), whereas dBET6 degrades BRD2, BRD3 and BRD4, equivalently (16).”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [16]
In the citing paper
“Later, they optimized the linker and found a more potent PROTAC (dBET6) that showed better efficacy against T-ALL compared with JQ1 [43].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [43]
In the citing paper
“Therefore, profiling the changes in global protein expression by proteomics will be helpful to appreciate the potential off-target toxicities of PROTACs [3, 4, 43].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citationSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationMonitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Cited by
Sorted by citations
Items 201–300 of 469
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30
Vasta, J. D., Corona, C. R., & Robers, M. B. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_14 · Cited by 31
Tong, J., Tan, X., Risnik, D., Gao, M., Song, X., Ermine, K., Shen, L., Wang, S., Yu, J., & Zhang, L. (2021) · Oncogene · doi:10.1038/s41388-021-02041-8 · Cited by 29
Morgan, M. A., Shiekhattar, R., Shilatifard, A., & Lauberth, S. M. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.008 · Cited by 32
Falcinelli, S. D., Peterson, J. J., Turner, A. W., Irlbeck, D. M., Read, J., Raines, S. L. M., James, K. S., Sutton, C., Sanchez, A., Emery, A., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 29
Cohesin regulates alternative splicing
Singh, A. K., Chen, Q., Nguyen, C. D., Meerzaman, D. M., & Singer, D. S. (2023) · Science Advances · doi:10.1126/sciadv.ade3876 · Cited by 29
Karim, R. M., Yang, L., Chen, L., Bikowitz, M. J., Lu, J., Grassie, D., Shultz, Z. P., Lopchuk, J. M., Chen, J., & Schönbrunn, E. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01999 · Cited by 28
Activity-based profiling of cullin–RING E3 networks by conformation-specific probes
Henneberg, L. T., Singh, J., Duda, D. M., Baek, K., Yanishevski, D., Murray, P. J., Mann, M., Sidhu, S. S., & Schulman, B. A. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01392-5 · Cited by 31
Transcriptional targeting of oncogene addiction in medullary thyroid cancer
Valenciaga, A., Saji, M., Yu, L., Zhang, X., Bumrah, C., Yilmaz, A. S., Knippler, C. M., Miles, W. O., Giordano, T. J., Cote, G. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122225 · Cited by 28
PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
Mancarella, C., Morrione, A., & Scotlandi, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216346 · Cited by 28
Peter, B., Eisenwort, G., Sadovnik, I., Bauer, K., Willmann, M., Rülicke, T., Berger, D., Stefanzl, G., Greiner, G., Hoermann, G., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26650 · Cited by 27
Self-citationLi, Z., Wang, B., Liang, H., & Han, L. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73479 · Cited by 27
PROTACs in gastrointestinal cancers
Chen, Y., Yang, Q., Xu, J., Tang, L., Zhang, Y., Du, F., Zhao, Y., Wu, X., Li, M., Shen, J., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.012 · Cited by 28
Reicher, A., Koren, A., & Kubicek, S. (2020) · Genome Research · doi:10.1101/gr.261503.120 · Cited by 27
Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
Shi, J., Song, S., Han, H., Xu, H., Huang, M., Qian, C., Zhang, X., Ouyang, L., Hong, Y., Zhuang, W., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00554 · Cited by 26
Wang, C., Xu, Q., Zhang, X., Day, D. S., Abraham, B. J., Lun, K., Chen, L., Huang, J. S., & Ji, X. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04349-4 · Cited by 26
Development of Rapid and Facile Solid‐Phase Synthesis of PROTACs via a Variety of Binding Styles
Xu, H., Kurohara, T., Takano, R., Yokoo, H., Shibata, N., Ohoka, N., Inoué, T., Naito, M., & Demizu, Y. (2022) · ChemistryOpen · doi:10.1002/open.202200131 · Cited by 26
Martella, N., Pensabene, D., Varone, M., Colardo, M., Petraroia, M., Sergio, W., Rosa, P. L., Moreno, S., & Segatto, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030750 · Cited by 27
Bagka, M., Choi, H., Héritier, M., Schwaemmle, H., Pasquer, Q. T. L., Braun, S. M. G., Scapozza, L., Wu, Y., & Hoogendoorn, S. (2023) · Nature Communications · doi:10.1038/s41467-023-39657-1 · Cited by 27
Discovery of a DCAF11-dependent cyanoacrylamide-containing covalent degrader of BET-proteins
Tin, G., Cigler, M., Hinterndorfer, M., Dong, K. D., Imrichová, H., Gygi, S. P., & Winter, G. E. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129779 · Cited by 26
Self-citationPerner, F., & Armstrong, S. A. (2020) · Cells · doi:10.3390/cells9122721 · Cited by 25
Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 26
Emerging roles of BET proteins in transcription and co‐transcriptional RNA processing
Eischer, N., Arnold, M., & Mayer, A. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1734 · Cited by 26
Self-citationHexim1, an RNA-controlled protein hub
Michels, A. A., & Bensaude, O. (2018) · Transcription · doi:10.1080/21541264.2018.1429836 · Cited by 24
Bauer, K., Hauswirth, A. W., Gleixner, K. V., Greiner, G., Thaler, J., Bettelheim, P., Filik, Y., Koller, E., Hoermann, G., Staber, P. B., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27385 · Cited by 29
Donczew, R., & Hahn, S. (2021) · eLife · doi:10.7554/elife.69619 · Cited by 24
Bauer, K., Berghoff, A. S., Preusser, M., Heller, G., Zielinski, C. C., Valent, P., & Grunt, T. W. (2021) · PubMed Central · Cited by 24
Zhu, Y., Lee, H., White, S. M., Weimer, A. K. K., Monte, E., Horning, A. M., Nevins, S. A., Esplin, E. D., Paul, K., Krieger, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00823-z · Cited by 24
In silico modeling of targeted protein degradation
Lv, W., Jia, X., Tang, B., Ma, C., Fan, X., Jin, X., Niu, Z., & Han, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117432 · Cited by 27
Ma, K., Han, X.-X., Han, X., & Zhou, S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308075 · Cited by 24
Dicer promotes genome stability via the bromodomain transcriptional co-activator BRD4
Gutbrod, M. J., Roche, B., Steinberg, J. I., Lakhani, A. A., Chang, K., Schorn, A. J., & Martienssen, R. A. (2022) · Nature Communications · doi:10.1038/s41467-022-28554-8 · Cited by 22
Shi, X., Wang, Y., Zhang, L., Zhao, W., Dai, X., Yang, Y., & Zhang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1021820 · Cited by 25
Zhu, X., Qi, C.-Y., Wang, R.-Y., Lee, J.-H., Shao, J., Bei, L.-X., Xiong, F., Nguyen, P. T., Li, G., Krakowiak, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111576 · Cited by 20
Shah, V., Giotopoulos, G., Osaki, H., Meyerhöfer, M., Meduri, E., Gallego-Crespo, A., Behrendt, M. A., Saura-Pañella, M., Tarkar, A., Schubert, B., et al. (2024) · Blood · doi:10.1182/blood.2022019306 · Cited by 23
Advancing Design Strategy of PROTACs for Cancer Therapy
Luo, H., Tian, Y., Abdullah, R., Zhang, B., Ma, Y., & Zhang, G. (2025) · MedComm · doi:10.1002/mco2.70258 · Cited by 24
Kim, S.-K., Liu, X., Park, J., Um, D., Kilaru, G., Chiang, C., Kang, M., Huber, K. M., Kang, K., & Kim, T.-K. (2021) · Science Advances · doi:10.1126/sciadv.abf7346 · Cited by 23
The molecular understanding of super-enhancer dysregulation in cancer.
Yoshino, S., & Suzuki, H. I. (2022) · PubMed Central · doi:10.18999/nagjms.84.2.216 · Cited by 23
Pooled endogenous protein tagging and recruitment for systematic profiling of protein function
Serebrenik, Y. V., Mani, D. R., Maujean, T., Burslem, G. M., & Shalem, O. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100651 · Cited by 21
Huang, M., Zeki, J. C., Sumarsono, N., Coles, G. L., Taylor, J. S., Danzer, E., Bruzoni, M., Hazard, F. K., Lacayo, N. J., Sakamoto, K. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2560 · Cited by 22
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Barghout, S. H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410082652 · Cited by 21
Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states
Li, K., Girardi, E., Kartnig, F., Grosche, S., Pemovska, T., Bigenzahn, J. W., Goldmann, U., Sedlyarov, V., Bensimon, A., Schick, S., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00386-8 · Cited by 21
Massafra, V., Tundo, S., Dietzig, A., Ducret, A., Jöst, C., Klein, C., Kontermann, R. E., Knoetgen, H., Steegmaier, M., Romagnani, A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000252 · Cited by 23
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells
Mahan, S. D., Riching, K. M., Urh, M., & Daniels, D. L. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_8 · Cited by 20
Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications
Negi, A., Kesari, K. K., & Voisin‐Chiret, A. S. (2022) · Applied Sciences · doi:10.3390/app12199674 · Cited by 21
Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader
Divakaran, A., Scholtz, C. R., Zahid, H., Lin, W., Griffith, E. C., Lee, R. E., Jr., Chen, T., Harki, D. A., & Pomerantz, W. C. K. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00300 · Cited by 21
Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia
Shi, Y., Liu, M., Li, M., Mao, Y., Ma, J., Long, R., Xu, M., Yang, Y., Wang, W., Zhou, Y., et al. (2024) · Chemical Science · doi:10.1039/d3sc06558h · Cited by 21
Graham, T. G. W., Dugast‐Darzacq, C., Dailey, G. M., Weng, B., Anantakrishnan, S., Darzacq, X., & Tjian, R. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.06.028 · Cited by 21
Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein
Shibata, N., Ohoka, N., Hattori, T., & Naito, M. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00703 · Cited by 21
BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML
Zhang, S., Zhao, Y., Heaster, T. M., Fischer, M. A., Stengel, K. R., Zhou, X., Ramsey, H. E., Zhou, M., Savona, M. R., Skala, M. C., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28005 · Cited by 21
Castillo-Guzman, D., Hartono, S. R., Frederick, M. H., Sanz, L. A., Sereiva, T., & Chedin, F. L. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.08.130583 · Cited by 25
Epigenetic control of pancreatic cancer metastasis
Krauß, L., Schneider, C., Heßmann, E., Saur, D., & Schneider, G. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10132-z · Cited by 20
MSL2 ensures biallelic gene expression in mammals
Sun, Y., Wiese, M., Hmadi, R., Karayol, R., Seyfferth, J., Greene, J. A. M., Erdogdu, N. U., Deboutte, W., Arrigoni, L., Holz, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06781-3 · Cited by 22
Application of PROTACs in target identification and validation
Liu, Y., Liang, J. Y., Zhu, R., Yang, Y., Wang, Y., Wei, W., Li, H., & Chen, L. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0010 · Cited by 21
Design, Synthesis, and Activity Evaluation of BRD4 PROTAC Based on Alkenyl Oxindole-DCAF11 Pair
Zhao, M., Ma, W., Liang, J., Xie, Y., Wei, T., Zhang, M., Qin, J., Lao, L., Tian, R., Wu, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01767 · Cited by 21
Kedaigle, A. J., Reidling, J. C., Lim, R. G., Adam, M., Wu, J., Wassie, B. T., Stocksdale, J. T., Casale, M., Fraenkel, E., & Thompson, L. M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz264 · Cited by 19
He, D.-D., Shang, X.-Y., Wang, N., Wang, G.-X., He, K.-Y., Wang, L., & Han, Z.-G. (2022) · Oncogene · doi:10.1038/s41388-022-02176-2 · Cited by 21
Lv, M., Hu, W., Zhang, S., He, L., Hu, C., & Yang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215716 · Cited by 19
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Gross, P. H., Sheets, K. J., Warren, N. A., Ghosh, S., Varghese, R. E., Wass, K. E., & Kadimisetty, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.048 · Cited by 19
Bressin, A., Jasnovidova, O., Arnold, M., Altendorfer, E., Trajkovski, F., Kratz, T. A., Handzlik, J. E., Hnisz, D., & Mayer, A. (2023) · Nature Communications · doi:10.1038/s41467-023-40633-y · Cited by 22
Self-citationMarsh, A. J., Пирогов, С. А., Kaur, Y., Ruffridge, A. J., Sajwan, S., Gibson, T. J., Hunt, G., Harrison, M. M., & Mannervik, M. (2024) · Molecular Cell · doi:10.1016/j.molcel.2025.05.009 · Cited by 22
Emerging insights into enhancer biology and function
Arnold, M., & Stengel, K. R. (2023) · Transcription · doi:10.1080/21541264.2023.2222032 · Cited by 20
CRISPR–ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia
Gilan, O., Talarmain, L., Bell, C. C., Neville, D., Knezevic, K., Ferguson, D. T., Boudes, M., Chan, Y.-C., Davidovich, C., Lam, E. Y. N., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01087-4 · Cited by 19
Challenges and Opportunities in NUT Carcinoma Research
Gu, B., & Hakun, M. (2021) · Genes · doi:10.3390/genes12020235 · Cited by 15
Wang, X., Wang, Q., Ran, K., Ren, J., Shi, Y., & Yu, L. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105238 · Cited by 18
Chen, J., He, H., Wei, A., Li, Y., Cheng, G., Qin, H., Zhong, H., Liu, H., Geng, M., Shen, A., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114259 · Cited by 18
Wang, J., Yu, Q., Qiu, Z., Dai, T., Wang, S., Yang, X. H., Evers, B. M., & Wu, Y. (2020) · Aging · doi:10.18632/aging.102630 · Cited by 18
Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders
Zhuang, Z., Byun, W. S., Kozicka, Z., Donovan, K. A., Dwyer, B. G., Thornhill, A. M., Jones, H. M., Jiang, Z., Zhu, X., Fischer, E. S., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202508427 · Cited by 17
Self-citationHiBiT-SpyTag: A Minimal Tag for Covalent Protein Capture and Degrader Development
Tsang, T., Huerta, F., Liu, Y., Che, J., Metivier, R. J., Ferrao, S., Donovan, K. A., Jones, L. H., Zerfas, B. L., & Nowak, R. P. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00084 · Cited by 19
Gold, S. R., & Shilatifard, A. (2024) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2024.102181 · Cited by 18
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lee, L., Hizukuri, Y., Severson, P. L., Powell, B., Zhang, C., Ma, Y., Narahara, M., Sumi, H., Hernandez, D., Rajkhowa, T., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.247346 · Cited by 17
Novel therapeutics and targets in myelofibrosis
Waksal, J. A., Harrison, C. N., & Mascarenhas, J. O. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2010068 · Cited by 17
The role of enhancer RNAs in epigenetic regulation of gene expression
Rahnamoun, H., Orozco, P., & Lauberth, S. M. (2020) · Transcription · doi:10.1080/21541264.2019.1698934 · Cited by 16
Recoules, L., Heurteau, A., Raynal, F., Karasu, N., Moutahir, F., Bejjani, F., Jariel‐Encontre, I., Cuvier, O., Sexton, T., Lavigne, A.-C., et al. (2022) · Journal of Cell Science · doi:10.1242/jcs.259456 · Cited by 17
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
Gao, J., Wang, M. Y., Ren, Y., Lwin, T., Li, T., Yan, J. C., Sotomayor, E. M., Duckett, D. R., Shah, B. D., Shain, K. H., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278743 · Cited by 16
Viral Hijacking of BET Proteins
Chen, I. P., & Ott, M. (2022) · Viruses · doi:10.3390/v14102274 · Cited by 17
Schwalm, M. P., Menge, A., Elson, L., Greco, F., Robers, M. B., Müller, S., & Knapp, S. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00450 · Cited by 15
Development of Versatile Solid-Phase Methods for Syntheses of PROTACs with Diverse E3 Ligands
Xu, H., Kurohara, T., Ohoka, N., Tsuji, G., Inoué, T., Naito, M., & Demizu, Y. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117293 · Cited by 16
The role of noncoding mutations in blood cancers
Rahman, S., & Mansour, M. R. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.041988 · Cited by 16
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation
Zheng, Y., Singh, A., Niu, Z., Marin, V. L., Young, J., Richardson, P. L., Hemshorn, M. L., Cooley, R. B., Karplus, P. A., Puvar, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02741 · Cited by 16
Sun, F., Wang, T., Wang, P., Shi, J., Shen, Y., Wang, G., Yang, B., Li, H., Zhang, Q., Chen, Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c11564 · Cited by 15
BET Protein-Mediated Transcriptional Regulation in Heart Failure
Ijaz, T., & Burke, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116059 · Cited by 15
To bind or not to bind: Cistromic reprogramming in prostate cancer
Shen, M., Demers, L.-K., Bailey, S. D., & Labbé, D. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.963007 · Cited by 15
Yan, Z., Lyu, X., Lin, D., Wu, G., Gong, Y., Ren, X., Xiao, J., Lou, J., Huang, H., Chen, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115381 · Cited by 14
Radzisheuskaya, A., Peña-Rømer, I., Lorenzini, E., Koche, R., Zhan, Y.-Q. A., Shliaha, P. V., Cooper, A. J., Fan, Z., Shlyueva, D., Johansen, J., et al. (2023) · EMBO Journal · doi:10.15252/embj.2023114221 · Cited by 13
Bromodomain proteins: protectors against endogenous DNA damage and facilitators of genome integrity
Lee, S. Y., Kim, J. J., & Miller, K. M. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00673-0 · Cited by 15
Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
Zhong, S., Peng, S., Chen, Z., Chen, Z., & Luo, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030498 · Cited by 14
Huang, F., Shao, W., Fujinaga, K., & Peterlin, B. M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001518 · Cited by 14
Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma
Choi, J. E., Verhaegen, M. E., Yazdani, S., Malik, R., Harms, P. W., Mangelberger, D., Tien, J. C.-Y., Cao, X., Wang, Y., Cieslik, M. P., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.01.003 · Cited by 13
Sun, D., Nikonova, A. S., Zhang, P., Deneka, A. Y., Fitzgerald, M. E., Michael, R. E., Lee, L., Lilly, A. C., Fisher, S. L., Phillips, A. J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0831 · Cited by 13
Transcriptional elongation control of hypoxic response
Soliman, S. H. A., Iwanaszko, M., Zheng, B., Gold, S. R., Howard, B. C., Das, M., Chakrabarty, R. P., Chandel, N. S., & Shilatifard, A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321502121 · Cited by 13
Advancing target validation with PROTAC technology
Spitz, M. L., Kashkush, A., & Benhamou, R. I. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490248 · Cited by 12
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1 -Fusion-Positive Lung Cancer
Iyer, S. R., Odintsov, I., Schoenfeld, A. J., Siau, E., Mattar, M. S., de Stanchina, E., Khodos, I., Drilon, A., Riely, G. J., Ladanyi, M., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0025 · Cited by 11
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11
Self-citationVogt, K. C., Panagiotakopoulou, M., Manzari, M. T., Perea, A. M., Hu, X., Yu, X., Raziuddin, R., LaPlant, Q. C., Ruiz, S. B., Raju, G. P., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2292 · Cited by 11
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
Waksal, J. A., & Mascarenhas, J. O. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00671-7 · Cited by 10
Rosenthal, Z. C., Fass, D. M., Payne, N. C., She, A., Patnaik, D., Hennig, K. M., Tesla, R., Werthmann, G. C., Guhl, C., Reis, S. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59110-7 · Cited by 12
Photo-Regulated Protacs: A Novel Tool for Temporal Control of Targeted Protein Degradation
Xu, H., Ohoka, N., Inoué, T., Yokoo, H., & Demizu, Y. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129778 · Cited by 11
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs
Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13
Self-citationA comprehensive primer and review of PROTACs and their In Silico design
Zattoni, J., Vottero, P., Carena, G., Uliveto, C., Pozzati, G., Morabito, B., Gitari, E., Tuszyński, J. A., & Aminpour, M. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108687 · Cited by 14
Metadata
- Authors
- Winter, G. E., Mayer, A., Buckley, D. L., Erb, M. A., Roderick, J. E., Vittori, S., Reyes, J. M., di Iulio, J., Souza, A., Ott, C. J., Roberts, J. M., Zeid, R., Scott, T. G., Paulk, J., Lachance, K., Olson, C. M., Dastjerdi, S., Bauer, S., Lin, C. Y., Gray, N. S., Kelliher, M. A., Churchman, L. S., & Bradner, J. E.
- Affiliations
- Austrian Academy of Sciences (AT)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Churchman, L. Stirling
- Bradner, James E.
- ORCID
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 67
- Issue
- 1
- Pages
- 5-18.e19
- ISSN
- 1097-2765 (ISSN-L)
- PMC
- PMC5663500
- OpenAlex
- W2733066269
- Cited by
- 465
- References
- 47
- Citations by year
- 2026: 43 · 2025: 59 · 2024: 44 · 2023: 54 · 2022: 66 · 2021: 59 · 2020: 43 · 2019: 50 · 2018: 42 · 2017: 5
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Molecular Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- William Lawrence and Blanche Hughes Foundation
- NIH (R01-HG007173, R01-GM117333, R01-CA176745, P01-CA109901)
- EMBO long-term fellowship (ALTF 39-2013)
- Damon Runyon Cancer Research Foundation (DRG-2196-14)
- Human Frontier Science Program (LT000314/2013-L)
- EMBO (ALTF858-2012)
- Swiss National Science Foundation Postdoc Mobility Fellowship
- American Cancer Society Post-doctoral fellowship (125087-PF-13-247-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- BET proteins, BRD4, transcription elongation, RNA polymerase II, CDK9, bromodomain inhibitors, JQ1, enhancers, T-cell leukemia, cancer therapy
- MeSH terms
- Bromodomain Containing Proteins, Animals, Antineoplastic Agents, DNA-Binding Proteins, Dose-Response Relationship, Drug, Female, Humans, Mice, Transgenic, Nuclear Proteins, Peptide Hydrolases, RNA Polymerase II, Time Factors, Transcription Factors, Transfection, Gene Expression Regulation, Leukemic, Mice, SCID, Mice, Inbred NOD, Cell Cycle Proteins, Jurkat Cells, Xenograft Model Antitumor Assays, Cyclin-Dependent Kinase 9, Ubiquitin-Protein Ligases, HCT116 Cells, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Protein Stability, HEK293 Cells, Proteolysis, Transcription Elongation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
